Arrowhead Pharmaceuticals at ASHG 2026

Oct 20–24, 2026 Montréal, Canada ~7.5k attendees Website

Arrowhead Pharmaceuticals at ASHG 2026 in Montréal: 1 presentation (1 featured symposium).

Organization	ASHG 2026 Attendance
Arrowhead Pharmaceuticals Pasadena, California	1 Senior Director of Translational Genetics & Data Science
arrowheadpharma.com\|LinkedIn Public company Arrowhead Pharmaceuticals (NASDAQ: ARWR) is a commercial-stage pharmaceutical company developing medicines that treat intractable diseases by silencing the genes that cause them. Its drug REDEMPLO is now listed in Germany's Lauer-Taxe database, letting doctors prescribe and get it reimbursed. › Its drug REDEMPLO is now listed in Germany's Lauer-Taxe database, letting doctors prescribe and get it reimbursed. 2026-08 · source Acquired an FDA Rare Pediatric Disease Priority Review Voucher, a tool that can speed a future FDA review. 2026-08 · source Licensed ARO-PNPLA3 worldwide to Madrigal, which will pay Arrowhead a $25 million upfront payment upon closing. 2026-05 · source Source: company newsroom Q3 FY2026 revenue $75.3M, up 171% year over year › Revenue nearly tripled, likely reflecting new licensing deals; no forward guidance was given. · 2026-08-04 “Revenue \| $ \| 75,253 \| $ \| 27,767” Source: results release Currently hiring: 76 open roles › Source: careers page	Symposium Wed Oct 21 8:15 am Part of Beyond GWAS: Translating Human Genetic into Therapeutic Targets and Clinical Development Introduction Room 517A/Level 5 …Congratulations to [name], on being elected President-Elect... see you all in Montreal, Canada! ... #ASHG2026…View post on LinkedInPosted Oct 23, 2025

Organization

ASHG 2026 Attendance

Arrowhead Pharmaceuticals

Pasadena, California

1 Senior Director of Translational Genetics & Data Science

arrowheadpharma.com|LinkedIn

Public company

Arrowhead Pharmaceuticals (NASDAQ: ARWR) is a commercial-stage pharmaceutical company developing medicines that treat intractable diseases by silencing the genes that cause them.

Its drug REDEMPLO is now listed in Germany's Lauer-Taxe database, letting doctors prescribe and get it reimbursed.

›

Its drug REDEMPLO is now listed in Germany's Lauer-Taxe database, letting doctors prescribe and get it reimbursed.

2026-08 · source

Acquired an FDA Rare Pediatric Disease Priority Review Voucher, a tool that can speed a future FDA review.

2026-08 · source

Licensed ARO-PNPLA3 worldwide to Madrigal, which will pay Arrowhead a $25 million upfront payment upon closing.

2026-05 · source

Source: company newsroom

Q3 FY2026 revenue $75.3M, up 171% year over year

›

Revenue nearly tripled, likely reflecting new licensing deals; no forward guidance was given. · 2026-08-04

“Revenue | $ | 75,253 | $ | 27,767”

Source: results release

Currently hiring: 76 open roles

›

Source: careers page

Symposium

Wed Oct 21
8:15 am

Part of Beyond GWAS: Translating Human Genetic into Therapeutic Targets and Clinical Development

Introduction

Room 517A/Level 5

…Congratulations to [name], on being elected President-Elect... see you all in Montreal, Canada! ... #ASHG2026…View post on LinkedInPosted Oct 23, 2025

Instantly find 20 buyers from Arrowhead Pharmaceuticals

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the American Society of Human Genetics. Submit a correction